| Fredericka Manor Care Center | |
| 111 Third Avenue, Chula Vista, California 91910 | |
| (619) 427-2777 | |
| Name | Fredericka Manor Care Center |
|---|---|
| Location | 111 Third Avenue, Chula Vista, California |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 174 |
| Occupancy Rate | 65.98% |
| Medicare ID (CCN) | 055354 |
| Legal Business Name | Front Porch Communities Operating Group Llc |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1720335789 |
| Organization Name | FRONT PORCH COMMUNITIES OPERATING GROUP LLC |
| Doing Business As | FREDERICKA MANOR CARE CENTER |
| Address | 111 3rd Ave, Chula Vista, CA 91910 |
| Phone Number | 619-427-2777 |
News Archive
Syngenta announced today that it plans to construct a new state-of-the-art biotechnology research facility adjacent to its existing research campus in Research Triangle Park, North Carolina. The $71 million investment, which is scheduled to begin in June 2011, will focus on discovering and developing new agronomic traits to bring innovative solutions to growers across the world.
A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.
A pilot study at the National Institute of Standards and Technology (NIST), in support of the National Cancer Institute's Early Detection Research Network (EDRN), has validated the measurement accuracy of new techniques that use mitochondrial DNA as an early indicator for certain types of cancer.
Avita Medical Ltd., the regenerative medicine company, today announced that the United States Food and Drug Administration (FDA) has approved the Company's investigational device exemption (IDE) feasibility study for the use of ReCell Spray-On-Skin in the treatment of hypertrophic dyspigmented scars: i.e., raised and/or discoloured scars.
› Verified 8 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Syngenta announced today that it plans to construct a new state-of-the-art biotechnology research facility adjacent to its existing research campus in Research Triangle Park, North Carolina. The $71 million investment, which is scheduled to begin in June 2011, will focus on discovering and developing new agronomic traits to bring innovative solutions to growers across the world.
A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.
A pilot study at the National Institute of Standards and Technology (NIST), in support of the National Cancer Institute's Early Detection Research Network (EDRN), has validated the measurement accuracy of new techniques that use mitochondrial DNA as an early indicator for certain types of cancer.
Avita Medical Ltd., the regenerative medicine company, today announced that the United States Food and Drug Administration (FDA) has approved the Company's investigational device exemption (IDE) feasibility study for the use of ReCell Spray-On-Skin in the treatment of hypertrophic dyspigmented scars: i.e., raised and/or discoloured scars.
› Verified 8 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 10.07 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 3.21 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 51.05 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.15 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.83 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 2.95 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0.8 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.4 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 8.8 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 98.1 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.13 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 22.67 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 7.94 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.38 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.55 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 77.7 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 98.25 | 82.93 |
News Archive
Syngenta announced today that it plans to construct a new state-of-the-art biotechnology research facility adjacent to its existing research campus in Research Triangle Park, North Carolina. The $71 million investment, which is scheduled to begin in June 2011, will focus on discovering and developing new agronomic traits to bring innovative solutions to growers across the world.
A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.
A pilot study at the National Institute of Standards and Technology (NIST), in support of the National Cancer Institute's Early Detection Research Network (EDRN), has validated the measurement accuracy of new techniques that use mitochondrial DNA as an early indicator for certain types of cancer.
Avita Medical Ltd., the regenerative medicine company, today announced that the United States Food and Drug Administration (FDA) has approved the Company's investigational device exemption (IDE) feasibility study for the use of ReCell Spray-On-Skin in the treatment of hypertrophic dyspigmented scars: i.e., raised and/or discoloured scars.
› Verified 8 days ago
Fredericka Manor Care Center Location: 111 Third Avenue, Chula Vista, California 91910 Phone: (619) 427-2777 | |
Sharp Chula Vista Med Ctr Snf Location: 751 Medical Center Court, Chula Vista, California 91911 Phone: (619) 502-3540 | |
Veterans Home Of California - Chula Vista Location: 700 East Naples Court, Chula Vista, California 91911 Phone: (619) 482-6010 | |